Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient?
In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on:
🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles.
🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy.
🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients.
📅 Save Your Spot for the Live Event!
Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman.
Session 1: July 8 at 6:00 pm ET: bit.ly/3SitVaC
Session 2: July 28 at 7:00 pm ET: bit.ly/4oIAcZo
